Decision: Favourable
Study Title:
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313)
NREC Code:
21-NREC-CT-132
Decision:
Favourable
Meeting Date:
03/11/2021
Study Type:
CT application
Principal Investigator:
Dr Anne Fortune
PI Institution:
MMHU
Sponsor:
MMHU